Analyst Ratings for Jazz Pharmaceuticals (JAZZ)
JAZZ Rating Summary
JAZZ Price Target Summary
- Highest: $263.00 (BofA Securities)
- Lowest: $188.00 (UBS)
- Average: $222.93
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$222.93 (+22.5%)
* Over Last 12-Mos
Rating Score: 8.4 / 10
Percentile Rank: 87%
Avg. $ Target:
$222.93 (+22.5%)
* Over Last 12-Mos
Rating Score: 8.4 / 10
Percentile Rank: 87%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2026 | Barclays | Etzer Darout | New Coverage | Overweight (N/A) |
224.00 (N/A) |
188.97 (182.01) |
-3.68% | Details |
| 11/24/2025 | UBS | Ashwani Verma | Downgrade | Neutral (Buy) |
188.00 (163.00) |
176.93 (182.01) |
2.87% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
